Why the study?
Does diagnostic magnetic resonance of the heart at 1.5 Tesla cause adverse events or alter electrical lead parameters in patients with MR conditional EnRhythm/Advisa pacemaker systems?
Observational (n=36)
No
Does diagnostic magnetic resonance of the heart at 1.5 Tesla cause adverse events or alter electrical lead parameters in patients with MR conditional EnRhythm/Advisa pacemaker systems?
Diagnostic MR of the heart at 1.5 Tesla appears safe in patients with the MR conditional EnRhythm/Advisa pacemaker system, causing no adverse events and only clinically irrelevant changes in lead parameters.
Answers are grounded in this paper and cite their sources.
Supports 1.5T CMR safety in MR-conditional pacemakers; hypothesis-generating, needs prospective confirmation before broader adoption.
BACKGROUND: No published data exist about the safety of diagnostic magnetic resonance (MR) of the heart performed in a larger series of patients implanted with MR conditional pacemakers (PM). The purpose of our study is to analyse safety and potential alterations of electrical lead parameters in patients implanted with the EnRhythm/Advisa MRI SureScan PM with 5086MRI leads (Medtronic Inc.) during and after MR of the heart at 1.5 Tesla. METHODS: Patients enrolled in this single center pilot study who underwent non-clinically indicated diagnostic MR of the heart were included in this analysis. Heart MR was performed for analyses of potential changes in right and left ventricular functional parameters under right ventricular pacing at 80 and 110 bpm. Atrial/ventricular sensing, atrial/ventricular pacing capture threshold [PCT], and pacing impedances were assessed immediately before, during, and immediately after MR, as well at 3 and 15 months post MR. RESULTS: Thirty-six patients (mean age 69 ± 13 years; high degree AV block 18 [50%]) underwent MR of the heart. No MR related adverse events occurred during MR or thereafter. Ventricular sensing differed significantly between the FU immediately after MR (10.3 ± 5.3 mV) and the baseline FU (9.8 ± 5.3 mV; p < 0.05). Despite PCT [V/0.4ms] was not significantly different between the FUs (baseline: 0.84 ± 0.27; in-between MR scans: 0.82 ± 0.27; immediately after MR: 0.84 ± 0.24; 3-month: 0.85 ± 0.23; 15-month: 0.90 ± 0.67; p = ns), 7 patients (19%) showed PCT increases by 100% (max. PCT measured: 1.0 V) at the 3-month FU compared to baseline. RV pacing impedance [Ω/5V] differed significantly at the FU in-between MR scans (516 ± 47), and at the 15-month FU (482 ± 58) compared to baseline (508 ± 75). CONCLUSION: The results of our study suggest MR of the heart to be safe in patients with the MR conditional EnRhythm/Advisa system, albeit although noticeable but clinically irrelevant ventricular PCT changes were observed.
No takes yet. Share an insight, caveat, or question.
Wollmann et al. (2014) conducted an observational in Patients with MR conditional pacemaker systems (n=36). Diagnostic magnetic resonance (MR) of the heart at 1.5 Tesla vs. Baseline (pre-MR) was evaluated on Ventricular sensing immediately after MR (mV) (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: